repaglinide has been researched along with Cardiovascular Diseases in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (22.22) | 29.6817 |
2010's | 4 (44.44) | 24.3611 |
2020's | 3 (33.33) | 2.80 |
Authors | Studies |
---|---|
Gnesin, F; Hemmingsen, B; Kähler, LKA; Madsbad, S; Thuesen, ACB | 1 |
Chi, Y; Hemmingsen, B; Ipsen, EØ; Madsen, KS; Metzendorf, MI; Pedersen-Bjergaard, U; Richter, B | 1 |
Chen, X; Chen, Y; He, S; Li, G; Qian, X; Shen, X; Xu, X; Zhang, B | 1 |
Huang, HK; Yeh, JI | 1 |
Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A | 1 |
Abdelmoneim, AS; Huang, Y; Light, P; Qiu, W; Simpson, SH | 1 |
Abdelmoneim, AS; Brocks, DR; Hasenbank, SE; Light, PE; Seubert, JM; Simpson, SH | 1 |
Ciccarelli, L; Crescenzi, G; Derosa, G; Fogari, R; Mugellini, A | 1 |
Barbieri, M; Grella, R; Paolisso, G; Passariello, N; Rizzo, MR | 1 |
3 review(s) available for repaglinide and Cardiovascular Diseases
Article | Year |
---|---|
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Metformin; Myocardial Infarction; Piperidines; Quality of Life; Randomized Controlled Trials as Topic; Stroke; Sulfonylurea Compounds | 2020 |
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
Topics: Acarbose; Bias; Carbamates; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Piperidines; Placebos; Randomized Controlled Trials as Topic; Risk | 2020 |
Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
Topics: Animals; ATP-Binding Cassette Transporters; Carbamates; Cardiovascular Diseases; Cricetinae; Cyclohexanes; Diabetes Mellitus, Type 2; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Ischemic Preconditioning, Myocardial; Isoindoles; Mice; Muscle, Smooth, Vascular; Myocytes, Cardiac; Nateglinide; Phenylalanine; Piperidines; Potassium Channels, Inwardly Rectifying; Rats; Receptors, Drug; Risk Factors; Sulfonylurea Compounds; Sulfonylurea Receptors; Tolbutamide | 2012 |
2 trial(s) available for repaglinide and Cardiovascular Diseases
Article | Year |
---|---|
Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin.
Topics: Blood Glucose; Carbamates; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Lipoproteins; Male; Metformin; Middle Aged; Piperidines; Prospective Studies; Risk Factors; Triglycerides | 2003 |
Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study.
Topics: Aged; Aged, 80 and over; Area Under Curve; Blood Glucose; Carbamates; Cardiovascular Diseases; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Diabetic; Eating; Female; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Piperidines; Sulfonylurea Compounds; Thiobarbituric Acid Reactive Substances | 2005 |
4 other study(ies) available for repaglinide and Cardiovascular Diseases
Article | Year |
---|---|
Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study.
Topics: Aged; Benzamides; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycoside Hydrolase Inhibitors; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Mortality; Nateglinide; Piperidines; Proportional Hazards Models; Retrospective Studies; Sulfonylurea Compounds; Thiazolidinediones | 2021 |
Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
Topics: Aged; Carbamates; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Mortality; Piperidines; Secretagogues; Sulfonylurea Compounds; Taiwan | 2019 |
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Morbidity; Myocardial Infarction; Piperidines; Registries; Retrospective Studies; Risk Factors; Stroke; Sulfonylurea Compounds; Tolbutamide | 2015 |
Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
Topics: Aged; Aged, 80 and over; Alberta; Blue Cross Blue Shield Insurance Plans; Carbamates; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Female; Gliclazide; Glyburide; Hospitalization; Humans; Hypoglycemic Agents; Male; Myocardial Ischemia; Piperidines; Proportional Hazards Models; Retrospective Studies; Risk; Universal Health Insurance | 2015 |